Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61—FUNGEMAX trial (France)Research in context

Summary: Background: New chemotherapeutic approaches are still needed to improve survival and quality of life in metastatic pancreatic ductal adenocarcinoma (mPDAC). In the absence of validated predictive biomarkers, first-line sequential treatment strategies may allow to delay chemoresistance and...

詳細記述

書誌詳細

主要な著者:	Julien Taieb, Simon Pernot, Frédéric Thuillier, Alexis Delattre, Erwan Vo-Quang, Caroline Petorin, Vincent Bourgeois, David Tougeron, Franck Audemar, Carole Vitellius, Laurent Mosser, Jérôme Desrame, Frédéric Di Fiore, Yves Rinaldi, Anna Pellat, Marion Bolliet, Fabienne Watelle, Hervé Perrier, Olivier Dubreuil, Come Lepage, Jean-Baptiste Bachet
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2026-06-01
シリーズ:	EClinicalMedicine
主題:	Sequential treatment Pancreatic cancer Nal-IRI Nab-paclitaxel Gemcitabine
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2589537026002464
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!